While our current study made use of a TLR7/8 agonist to enhance antigen presentation and immune activation, previous studies, including our own, have demonstrated that STING agonists also serve as potent immune adjuvants.[5, 59] We recently reported the co‐delivery of a STING agonist with mRNA in liver‐targeting nanoparticles to reprogram the tolerogenic environment, highlighting the use of additional immunomodulators to shape the immune responses in cancer.[5] We also demonstrated that these particles confer memory T cell responses that can be adoptively transferred. Here, TLR7 is linked to cancer.